Pivotal Week Ahead for Skye Bioscience with Key Data and Financial Results

Skye Bioscience faces a defining period with two critical events scheduled this week. The biotechnology firm is set to present clinical trial findings for its obesity treatment, Nimacimab, at ObesityWeek 2025 today. This presentation will be followed by the release of its third-quarter 2025 financial results on Monday.

New findings from the CBeyond Phase 2 study demonstrate encouraging outcomes for Nimacimab when used alongside Semaglutide. This combination therapy significantly addressed weight regain following treatment cessation, showing marked improvement over Semaglutide alone.

Key metrics from the study include:
* Patients regained only 18.1% of Read more...